Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SELPERCATINIB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 15 adverse event reports in the FDA FAERS database where SELPERCATINIB was used for Neoplasm malignant.

Most Reported Side Effects for SELPERCATINIB

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 106 9.8% 31 32
Death 90 8.3% 88 1
Hypertension 58 5.4% 1 18
Hypersensitivity 55 5.1% 4 34
Diarrhoea 54 5.0% 10 19
Fatigue 51 4.7% 2 16
Rash 49 4.5% 2 17
Hepatic function abnormal 42 3.9% 3 21
Alanine aminotransferase increased 38 3.5% 4 19
Pyrexia 38 3.5% 1 18
Aspartate aminotransferase increased 37 3.4% 4 17
Ascites 33 3.0% 3 7
Dry mouth 32 3.0% 5 10
Electrocardiogram qt prolonged 32 3.0% 1 18
Thrombocytopenia 31 2.9% 5 16

Other Indications for SELPERCATINIB

Non-small cell lung cancer (231) Product used for unknown indication (214) Lung neoplasm malignant (158) Medullary thyroid cancer (116) Thyroid cancer (59) Lung adenocarcinoma (50) Non-small cell lung cancer stage iv (23) Lung adenocarcinoma stage iv (20) Lung carcinoma cell type unspecified stage 0 (19) Non-small cell lung cancer metastatic (18)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

SELPERCATINIB Full Profile All Neoplasm malignant Drugs SELPERCATINIB Demographics SELPERCATINIB Timeline